Twist Bioscience Corporation
TWST · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.18 | -0.61 | 1.86 |
| FCF Yield | -1.43% | -0.48% | -0.73% | -0.86% |
| EV / EBITDA | -60.48 | 79.00 | -67.83 | -104.03 |
| Quality | ||||
| ROIC | -5.30% | -5.22% | -7.79% | -6.27% |
| Gross Margin | 51.35% | 53.40% | 49.60% | 48.29% |
| Cash Conversion Ratio | 0.44 | -0.07 | 0.33 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.39% | 15.44% | 15.13% | 15.23% |
| Free Cash Flow Growth | -129.45% | 38.32% | 27.71% | -36.80% |
| Safety | ||||
| Net Debt / EBITDA | 4.08 | -4.67 | 3.99 | 5.53 |
| Interest Coverage | 0.00 | 0.00 | -290.63 | -1,443.50 |
| Efficiency | ||||
| Inventory Turnover | 1.70 | 1.73 | 2.24 | 1.95 |
| Cash Conversion Cycle | 84.27 | 74.77 | 73.07 | 71.31 |